KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Supernus Pharmaceuticals (SUPN) Other Accumulated Expenses: 2013-2025

Historic Other Accumulated Expenses for Supernus Pharmaceuticals (SUPN) over the last 8 years, with Sep 2025 value amounting to $26.3 million.

  • Supernus Pharmaceuticals' Other Accumulated Expenses was N/A to $26.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $26.3 million, marking a year-over-year change of. This contributed to the annual value of $4.3 million for FY2023, which is 74.60% down from last year.
  • As of Q3 2025, Supernus Pharmaceuticals' Other Accumulated Expenses stood at $26.3 million, which was down 4.99% from $27.7 million recorded in Q2 2025.
  • Over the past 5 years, Supernus Pharmaceuticals' Other Accumulated Expenses peaked at $27.7 million during Q2 2025, and registered a low of $710,000 during Q3 2023.
  • For the 3-year period, Supernus Pharmaceuticals' Other Accumulated Expenses averaged around $10.6 million, with its median value being $6.1 million (2023).
  • In the last 5 years, Supernus Pharmaceuticals' Other Accumulated Expenses plummeted by 91.33% in 2023 and then soared by 664.70% in 2025.
  • Quarterly analysis of 5 years shows Supernus Pharmaceuticals' Other Accumulated Expenses stood at $20.1 million in 2021, then dropped by 16.24% to $16.9 million in 2022, then plummeted by 74.60% to $4.3 million in 2023, then rose by 27.55% to $3.6 million in 2024, then soared by 664.70% to $26.3 million in 2025.
  • Its Other Accumulated Expenses was $26.3 million in Q3 2025, compared to $27.7 million in Q2 2025 and $4.7 million in Q1 2025.